Skip to content
drillr.ai
Sign up

BIIB

BIOGEN INC.

NASDAQ · Healthcare · Drug Manufacturers - General · US

$215.50
−1.62%
Ask drillr

  • Sep 17, 2026, 20:15 UTC

    Biogen Inc. announced the publication of a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology, showing reduction in proteinuria and stabilized kidney function in adolescents with C3G or primary IC-MPGN.

    Source:

  • Sep 16, 2026, 07:44 UTC

    Eisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.

    Source:

  • Sep 10, 2026, 06:15 UTC

    NICE said it was unable to recommend omaveloxolone for Friedreich's ataxia on the NHS in England after manufacturer Biogen withdrew its evidence submission, but is ready to reopen the assessment if new evidence is submitted.

    Source:

  • Aug 26, 2026, 09:31 UTC

    Japan's Ministry of Health, Labour and Welfare expert panel deliberated on approval of Eisai and Biogen's Alzheimer's drug Leqembi subcutaneous injection formulation, which would allow home administration.

    Source:

  • Aug 25, 2026, 23:35 UTC

    Veeva Systems announced that Biogen has selected Veeva Vault CRM globally.

    Source:

  • Aug 25, 2026, 14:45 UTC

    The Irish Health Service Executive (HSE) approved reimbursement of Biogen's drug Skyclarys for patients with Friedrich's Ataxia, announced on 25 August 2026.

    Source:

  • Aug 6, 2026, 22:15 UTC

    Biogen Inc. completed its acquisition of RayThera Inc., a privately held biotechnology company focused on immunology therapies.

    Source:

  • Aug 1, 2026, 08:21 UTC

    Amundi increased its stake in Biogen Inc. by 38.2% during the first quarter, acquiring an additional 218,398 shares, as disclosed in a recent SEC filing.

    Source:

  • Jul 29, 2026, 10:00 UTC

    Biogen reported second-quarter revenue of $2.74 billion, beating market expectations of $2.47 billion.

    Source:

  • Jul 15, 2026, 15:55 UTC

    Biogen presented detailed phase II study data for its Alzheimer's drug diranersen, reaffirming a setback, and announced plans to advance the drug into phase III trials despite missed goals.

    Source:

  • Jul 14, 2026, 02:23 UTC

    Eisai and Biogen received FDA approval for a subcutaneous injection version of Alzheimer's drug lecanemab (Leqembi) for use in early treatment, with a US launch planned for late August 2026.

    Source:

  • Jun 26, 2026, 13:56 UTC

    Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.

    Source:

  • Jun 17, 2026, 22:59 UTC

    Biogen Inc. agreed to acquire RayThera Inc. for up to $1 billion.

    Source:

  • Jun 5, 2026, 00:00 UTC

    AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.

  • Jun 4, 2026, 11:30 UTC

    Biogen Inc. received FDA Breakthrough Therapy Designation for its drug salanersen for spinal muscular atrophy.

    Source:

  • Jun 3, 2026, 11:30 UTC

    Biogen Inc. announced that fourteen abstracts on its nephrology portfolio, including EMPAVELI and felzartamab, were accepted for presentation at the ERA and ATC congresses.

    Source: